For women with ovarian cancer, the addition of bevacizumab to standard chemotherapy results in significantly improved progression-free survival (PFS).
Your search for bevacizumab returned 72 results
Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who have progressed after discontinuation of first-line bevacizumab and chemotherapy.
The systemic safety of bevacizumab appears to be similar to that of ranibizumab as intravitreal therapy for neovascular age-related macular degeneration (AMD).
Adjuvant bevacizumab increases overall survival in cervical cancer and improves progression-free survival in glioblastoma.
No evidence of infection, inflammation when bevacizumab is stored at 4 Celsius for a week
At two years of follow-up, diabetes-related clinically significant macular edema (CSME) is more effectively improved by intravitreous bevacizumab than with macular laser therapy (MLT).
Persistent diabetic macular edema more likely with bevacizumab than aflibercept or ranibizumab
After completion of the initial bevacizumab treatment cycle, there was a significant reduction in epistaxis severity scores and RBC transfusion requirements.
Both linked to improvements in visual acuity; only triamcinolone tied to sustained improvement in CMT
For patients with HIV-associated Kaposi’s sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients.
- Loading...
